UK: European Life Science Companies Selling Out To Large US Pharmas?

Last Updated: 13 March 2008

Sarika Patel
National Head of Technology
Grant Thornton

The easiest exit for European life science companies has been to sell out to large US pharmas. But could solutions such as greater collaboration or more public/private financing enable Europe to grow its own world-beating corporations?

Europe – and in particular the UK – has one of the most exciting and vibrant research populations in the world of life sciences. Fresh ideas from university laboratories have produced a host of successful spin-out biotech groups, significant drugs and the occasional blockbuster. The industry has developed from a few fledgling companies into a genuine pipeline of treatments for some of the world's largest pharmaceutical companies.

Yet, while the European life sciences industry is no flash in the pan, being more than a couple of decades old and having seen its share of boom and bust cycles, it has yet to develop a world-beating company with a pipeline of its own along the lines of US corporations such as Genentech or Genzyme. At a certain stage in a successful life science company's development, a sell out to one of the large corporations is almost inevitable. Two recent deals prove the point: AstraZeneca's purchase of Arrow Therapeutics for $150 million and Genzyme's proposed purchase of Bioenvision. "A key reason for this is that the appetite is not there from the venture capitalists and public market to fund the development of drugs all the way through to market," explains Neil McInnes, Corporate Finance Senior Manager at Grant Thornton. "Often the easier option is to flip it to a big pharma group when development gets to phase two or phase three. Testing on animals and humans has a high cost in terms of both finance and time, with treatments in Europe requiring regulatory approval from the European Medicine Agency (EMEA) as well as individual country regulators, such as the UK's National Institute for Health and Clinical Excellence (NICE). Combined with the cost of marketing new drugs and the overall risk associated with getting to that stage, investors often look for exit routes before reaching the market. At the same time, big pharma are actively on the look out for novel products to fill their development pipelines, which can often lead to a deal being done."

European investors do not have the experience of their US counterparts in funding drug development and find it difficult to handle the long lead times before cash flows back to them. "There are two big issues – investors' appetite for risk and management's experience of developing drugs beyond the early stage of research," argues Ken Powell, head of Arrow Therapeutics. "The US industry is very good at spotting opportunities and spending heavily to get the drug to market. It is hard to envisage the sort of investment from Europe that could create a business like Genzyme or Genentech."

The lack of experience also manifests itself in another issue in Europe – a relative lack of steadfastness. "All projects hit problems in development at some stage and need more money," continues Ken. "There can be a sense of panic if you hit a delay in a European company. The extra investment is not forthcoming from European investors unless they have the reassurance of a US investor alongside."

As a result, the sell-out option has become well established in Europe. The big pharmaceutical companies see this as a key element of their development pipeline – AstraZeneca, for instance, has funds explicitly for buying out new treatments, technologies and companies from the life sciences sector. So, what's the solution?

1. More Sophisticated Financing

Many experts argue that the US has more innovative techniques available for financing life sciences companies. For example, it is possible to combine public and private financing, thanks to the fact that investors can share preemption rights – the rights of existing shareholders to subscribe for new stock ahead of other investors. Hedge funds are also active in the US life sciences arena in a way that they have yet to emerge in Europe. This is due to the US market being larger and better developed. "The issue in Europe is that the sector is relatively small and many investors have come to it relatively recently," says Ken. "The US investors have been around much longer and have a deeper understanding of the issues."

2. Specialisation

A number of European companies are taking drugs to market, but they tend to focus in niche areas. In Scotland, Grant Thornton advises Ardana, a company that specialises in developing and marketing therapeutics in the area of reproduction. "The key difference when you are targeting a niche market is that the infrastructure, and therefore the funding required, is significantly reduced, allowing the company to take their products all the way to market," reflects Neil McInnes.

3. Promote Local Success

Switzerland boasts a vibrant life sciences sector based on the success of local companies – although one of the most prominent, Serono, recently sold itself to Merck of Germany. A similar clustering effect is being attempted in countries like Norway and Denmark. In contrast, in the UK, potential beacons in the sector are bought out and the company loses visibility, such as Celltech, which was bought by UCB of Belgium, and Cambridge Antibody (CAT), which was purchased by AstraZeneca.

4. A Move Towards Collaboration

Another solution is that the industry organically, or guided by informed advisers, moves towards collaborations to create a cluster of projects in a therapeutic or research area thereby giving the group critical mass. An example of this would be Antisoma: it is listed on the main market and, despite its ups and downs, demonstrates a model that shows resilience through the aggregation of cancer targets.

Although these four suggestions outline ways in which to create a UK world-beating company with a pipeline of its own along the lines of US corporations, it has to be seen in the wider context. Today, the US has the strongest biotechnology sector, but in the future it will undoubtedly be India and China that takes on this mantle. So a different approach may be that the most efficient business model for European life sciences is the one that has already evolved: developing companies to a critical stage and then selling out. If all the stakeholders approve and we can retain the unique skills and jobs in pharmaceutical R&D, and the investors have a satisfactory exit, why should we really worry?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions